info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Anticholinergic Drugs Companies

The report provides a comprehensive overview of the market, including the types of anticholinergic drugs, their applications, and the route of administration. The report also highlights the key players in the market, such as Astellas Pharma Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd, and Mylan N.V

Anticholinergic Drugs  Key CompaniesLatest anticholinergic drugs Companies Update



  • January 2023: The Phase 3 CARTITUDE-4 study comparing CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) to pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory The Independent Data Monitoring Committee advised unblinding the research since the primary endpoint was met.




  •  December 2022: The Janssen Pharmaceutical Companies of Johnson & Johnson, a major supplier of anticholinergic medications, announced that talquetamab, for the treatment of patients with relapsed or refractory multiple myeloma, had been submitted as a biologic in a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). Talquetamab is an experimental, over-the-counter (ready to use), bispecific T-cell engager antibody that simultaneously targets CD3 on T cells and GPRC5D, a new therapeutic target that is overexpressed on myeloma cells but not on certain normal cells.




  • November 2022: The world's largest and most diversified healthcare products company, Johnson & Johnson, and Abiomed, a pioneer in ground-breaking heart, lung, and kidney support technologies, announced today that they have entered into a definitive agreement under which Johnson & Johnson will purchase all of Abiomed's outstanding shares through a tender offer for an upfront cash payment of $380 per share, or a total purchase price of $1.1 trillion. A non-tradeable contingent value right (CVR) will also be given to Abiomed shareholders, entitling the holder to earn up to $35 in cash per share in the event that specified commercial and clinical milestones are reached. The boards of directors of both firms unanimously authorized the deal.List of anticholinergic drugs Key companies in the market

  • Johnson & Johnson Services Inc.

  • Boehringer Ingelheim International GmbH

  • Pfizer Inc.

  • Astellas Pharma Inc.

  • Allergan Plc

  • GlaxoSmithKline Plc

  • Teva Pharmaceutical Industries  Ltd

  • Sanofi

  • Novartis AG

  • Mylan N.V.

  • Cogentix Medical Inc

  • Hisamitsu Pharmaceutical Co. Inc.

  • Macleods Pharmaceuticals Ltd.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.